Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating …

  • Independent Data Monitoring Committee recommended on September 30, 2020 that the study continue into Phase 3 based on a positive evaluation of safety and tolerability data from the Phase 2 lead-in
  • Initial Phase 3 results may be available as early as the end of 2020; results for the primary endpoint are expected in the first quarter of 2021, with current estimates at January 2021
  • If successful, VIR-7831 has the potential to advance outpatient treatment for COVID-19
  • Patient enrollment underway; website live at https://vircovid19study.com/

SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully

Read More
Read More

MoU signed to set up TDAC by Department of Science and Technology and Biotechnology

More News
05 Oct 2020 | 4:31 PM

Imphal, Oct 5 (UNI) Manipur Chief Minister N. Biren Singh today inspected Biofloc Fish Farming at the residence of fish farmer Longjam Boss Meitei at Wangjoi Thounaojam Leikai, Imphal West.

see more..

05 Oct 2020 | 4:16 PM

Balasore , Oct 5 (UNI) Supersonic Missile Assisted Release of Torpedo (SMART) was successfully flight tested today at 11.45 hrs from Wheeler Island off the coast of Odisha.
All the mission objectives, including missile flight up to the range and altitude, separation of the nose cone, release of Torpedo and deployment of Velocity Reduction Mechanism (VRM) have been met perfectly, ITR sources said .

see more..

05 Oct 2020 | 4:07 PM

Kolkata, Oct 05 (UNI) McDonald’s India – North & East, owned and operated by Connaught Plaza Restaurants, has introduced digital menu boards in its restaurants as a part of its restaurant reimaging

Read More
Read More

Emerging biotechnology company Biocytogen raised 142 million dollars (USD) in support of Project Integrum

Press release content from PR Newswire. The AP news staff was not involved in its creation.

BEIJING and BOSTON, Sept. 24, 2020 /PRNewswire/ — In August, Beijing Biocytogen Biotechnology Co., Ltd. (“Biocytogen”) announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.

Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against all notoriously difficult druggable targets. Taking full advantage of Biocytogen’s integrated technology platforms for antibody discovery, Project Integrum will launch pre-clinical efforts into over 1,000 human diseases currently affecting countless lives.

Meticulous screening of antibody candidates both in vivo and in vitro improves clinical translatability dramatically. At the core of Biocytogen lie the humanized antibody RenMab Mouse

Read More
Read More